Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Pilot Test of a Community-based Buprenorphine Treatment Intervention

This study has been completed.
Sponsor:
Collaborators:
National Institute on Drug Abuse (NIDA)
City University of New York, School of Public Health
Washington Heights Corner Project
Information provided by (Responsible Party):
Albert Einstein College of Medicine, Inc.
ClinicalTrials.gov Identifier:
NCT01761110
First received: January 2, 2013
Last updated: June 24, 2015
Last verified: June 2015
  Purpose
The main goal of this study is to pilot test the community-based buprenorphine treatment (CBBT) intervention, examining buprenorphine treatment initiation, opioid use, and HIV risk behaviors. Two groups of participants will be followed for 60 days, with 3 research visits. One group will be enrolled prior to the CBBT intervention (pre-intervention), and one group after the CBBT intervention (post-intervention). Data sources will include questionnaires, urine toxicology tests, and medical record data. We hypothesize that compared to the participants in the pre-intervention group, participants in the post-intervention group will be more likely to initiate buprenorphine treatment, reduce opioid use, and reduce high-risk HIV risk behaviors.

Condition Intervention
Opioid Dependence
Injection Drug Use
Behavioral: Community-based buprenorphine treatment (CBBT) intervention

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Development of a Community-based Buprenorphine Treatment Intervention

Resource links provided by NLM:


Further study details as provided by Albert Einstein College of Medicine, Inc.:

Primary Outcome Measures:
  • initiation of buprenorphine treatment [ Time Frame: 60 days ]
    Medical record information will be extracted to determine initiation of buprenorphine treatment, which will be defined as a visit with a medical provider in which buprenorphine is prescribed.


Secondary Outcome Measures:
  • opioid use [ Time Frame: 60 days ]
    Opioid use will be determined via self-report using the Addiction Severity Index and via urine specimens (e.g., urine toxicology testing).


Other Outcome Measures:
  • HIV risk behaviors [ Time Frame: 60 days ]
    Drug- and sex-related HIV risk behaviors will be assessed using a standardized risk assessment tool used in NIDA's Clinical Trials Network.


Enrollment: 77
Study Start Date: December 2012
Study Completion Date: February 2014
Primary Completion Date: February 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Pre-intervention
Participants will be enrolled prior to the implementation of the community-based buprenorphine treatment (CBBT) intervention.
Experimental: Post-intervention
Participants will be enrolled after implementing the community-based buprenorphine treatment (CBBT) intervention
Behavioral: Community-based buprenorphine treatment (CBBT) intervention
Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • at least 18 years old
  • English or Spanish fluency
  • ever injected drugs
  • not receiving buprenorphine treatment (no prescribed buprenorphine in the previous 6 months)
  • clients of our collaborating community-based organization
  • interested in buprenorphine treatment

Exclusion Criteria:

  • pregnant
  • taking more than 60mg of methadone daily in the previous 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01761110

Locations
United States, New York
Washington Heights Corner Project
New York, New York, United States, 10033
Sponsors and Collaborators
Albert Einstein College of Medicine, Inc.
National Institute on Drug Abuse (NIDA)
City University of New York, School of Public Health
Washington Heights Corner Project
Investigators
Principal Investigator: Chinazo Cunningham, MD, MS Albert Einstein College of Medicine, Inc.
  More Information

Responsible Party: Albert Einstein College of Medicine, Inc.
ClinicalTrials.gov Identifier: NCT01761110     History of Changes
Other Study ID Numbers: R34DA031066 ( US NIH Grant/Contract Award Number )
Study First Received: January 2, 2013
Last Updated: June 24, 2015

Keywords provided by Albert Einstein College of Medicine, Inc.:
Opioid dependence
Injection drug use
Buprenorphine
Opioid agonist treatment
Access to care
HIV risk behaviors
Opioids

Additional relevant MeSH terms:
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists

ClinicalTrials.gov processed this record on May 22, 2017